4.3 Coronary Artery Disease, Stable Angina & Post-ACS Outpatient Management
Key Takeaways
- Chronic Coronary Disease (CCD) / Stable Ischemic Heart Disease manifests as predictable, exertional substernal chest discomfort relieved by rest or sublingual nitroglycerin within 5 minutes, driven by myocardial oxygen supply-demand mismatch across a fixed atherosclerotic coronary stenosis.
- Atypical anginal equivalents—including unexplained exertional dyspnea, extreme fatigue, nausea, diaphoresis, and altered mental status—predominate in older adults, females, and patients with diabetic autonomic neuropathy, mandating a low threshold for diagnostic ECG and troponin testing.
- First-line anti-anginal medical therapy consists of Beta-blockers (titrated to a resting heart rate of 55–60 bpm) to reduce myocardial oxygen demand, supplemented by dihydropyridine CCBs or long-acting nitrates (requiring a 10–14 hour nitrate-free interval to prevent tolerance) when symptoms persist.
- Short-acting sublingual nitroglycerin (0.3–0.4 mg PRN every 5 minutes up to 3 doses) is prescribed for acute anginal episodes; concurrent use of Phosphodiesterase-5 (PDE-5) inhibitors (sildenafil within 24h, tadalafil within 48h) is an absolute contraindication due to life-threatening refractory hypotension.
- Long-term post-ACS outpatient management requires five core disease-modifying pillars: (1) Dual Antiplatelet Therapy (DAPT) with Aspirin + P2Y12 inhibitor for at least 12 months, (2) High-intensity statin, (3) Beta-blocker for ≥3 years (indefinitely if LVEF ≤40%), (4) ACE inhibitor/ARB, and (5) Mineralocorticoid receptor antagonist for LVEF ≤40% with clinical HF or diabetes.
Coronary Artery Disease, Stable Angina & Post-ACS Outpatient Management
Coronary Artery Disease (CAD) remains the principal etiology of cardiovascular morbidity, congestive heart failure, and premature death across the adult-gerontology lifespan. Atherosclerotic coronary plaque progression spans a continuum from asymptomatic subclinical atheroma to Chronic Coronary Disease (CCD) (stable angina) and life-threatening Acute Coronary Syndromes (ACS) (unstable angina, Non-ST-Segment Elevation Myocardial Infarction [NSTEMI], and ST-Segment Elevation Myocardial Infarction [STEMI]).
For the Adult-Gerontology Primary Care Nurse Practitioner (AGPCNP), outpatient clinical practice focuses on diagnostic risk stratification, optimizing anti-anginal pharmacotherapy, recognizing atypical anginal equivalents in vulnerable older adults, and executing comprehensive post-ACS disease-modifying management.
1. Pathophysiology of Coronary Atherosclerosis & Myocardial Ischemia
Myocardial perfusion is dictated by the dynamic balance between myocardial oxygen supply (coronary blood flow, arterial oxygen content, diastolic perfusion time) and myocardial oxygen demand ($\text{MVO}_2$) (heart rate, myocardial contractility, left ventricular wall tension / afterload).
+-----------------------------------------------------------------------------+
| MYOCARDIAL OXYGEN SUPPLY-DEMAND CASCADE |
| |
| OXYGEN DEMAND (MVO2) FACTORS: OXYGEN SUPPLY FACTORS: |
| - Heart Rate (HR) - Coronary Artery Diameter |
| - Systolic Wall Tension (Afterload) - Diastolic Perfusion Time |
| - Left Ventricular Contractility - Aortic Diastolic Pressure |
| - Hemoglobin & Oxygen Saturation|
| | |
| v |
| [SUPPLY-DEMAND IMBALANCE] ---> Transient Myocardial Ischemia |
| - Anaerobic metabolism & lactic acidosis |
| - Subendocardial sensory nerve stimulation |
| - ANGINA PECTORIS |
+-----------------------------------------------------------------------------+
Spectrum of Coronary Lesions:
- Fixed Stable Stenosis: Flow-limiting atherosclerotic plaque (typically $\ge 70%$ luminal diameter narrowing, or $\ge 50%$ of left main). Resting flow is maintained, but coronary blood flow reserve cannot increase during exertion, provoking predictable exertional angina.
- Unstable Plaque Rupture / Erosion: Thin fibrous cap atheroma (rich in lipid core and inflammatory macrophages) fissures, exposing subendothelial collagen and von Willebrand factor, triggering platelet adhesion, aggregation, and acute occlusive thrombus formation (Acute Coronary Syndrome).
2. Clinical Evaluation of Chest Pain & Atypical Presentations
Accurate classification of chest pain guides the urgency of diagnostic evaluation and prevents catastrophic misdiagnoses.
+-----------------------------------------------------------------------------+
| DIAMOND-FORRESTER CHEST PAIN CLASSIFICATION |
| |
| CRITERIA: |
| 1. Substernal chest discomfort with characteristic quality and duration |
| (pressure, squeezing, heaviness, tightness lasting 2-10 minutes) |
| 2. Provoked by physical exertion or emotional stress |
| 3. Relieved by rest or sublingual nitroglycerin within 5 minutes |
| |
| CATEGORIES: |
| * TYPICAL ANGINA (Definite) ---> Meets ALL 3 criteria |
| * ATYPICAL ANGINA (Probable) ---> Meets 2 of 3 criteria |
| * NON-CARDIAC CHEST PAIN ---> Meets 0 or 1 criterion |
+-----------------------------------------------------------------------------+
Anginal Equivalents & Geriatric Presentation Nuances:
In older adults ($>75$ years), females, and individuals with long-standing diabetes mellitus (due to cardiac autonomic neuropathy), traditional substernal "crushing" chest pain is frequently absent. Instead, patients present with anginal equivalents:
- Unexplained exertional dyspnea (most common anginal equivalent).
- Sudden profound, unaccustomed fatigue or generalized weakness.
- Epigastric discomfort, nausea, indigestion, or heartburn.
- Diaphoresis, presyncope, or acute lightheadedness.
- Acute delirium or sudden functional decline in frail elders.
[!WARNING] Diagnostic Pitfall in Geriatric Patients: Never dismiss sudden-onset dyspnea, nausea, or acute confusion in an older adult or diabetic patient as benign gastroenteritis or chronic aging. Always obtain an immediate 12-lead ECG and consider cardiac biomarkers.
3. Diagnostic Testing Modalities & Non-Invasive Risk Stratification
Selecting the appropriate diagnostic pathway depends on the patient's pre-test probability of CAD, baseline ECG readability, and physical exercise capacity.
+-----------------------------------------------------------------------------+
| DIAGNOSTIC ALGORITHM FOR SUSPECTED STABLE CAD |
| |
| [SUSPECTED STABLE CAD PATIENT] |
| | |
| v |
| [INITIAL 12-LEAD ECG] |
| | |
| +--------------------------+--------------------------+ |
| | | |
| v v |
| [NORMAL BASELINE ECG &] [ABNORMAL BASELINE ECG]|
| [ABLE TO EXERCISE] - LBBB, LVH with strain|
| | - Digoxin, WPW, pacing |
| v - Unable to exercise |
| [EXERCISE TREADMILL TEST (ETT)] | |
| - Standard Bruce Protocol v |
| - Positive: >= 1 mm horizontal / [STRESS IMAGING] |
| downsloping ST-depression - Stress Echocardiogram|
| - Nuclear SPECT / PET |
| - Pharmacologic Stress|
| (Regadenoson/Dobut) |
| | |
| v |
| [ANATOMIC IMAGING] |
| - Coronary CTA (CCTA) |
| - Invasive Angiography|
+-----------------------------------------------------------------------------+
Diagnostic Modality Comparison Table
| Modality | Indication & Patient Selection | Diagnostic Findings & Criteria | Advantages & Limitations |
|---|---|---|---|
| Exercise ECG Stress Testing (Bruce Protocol) | Normal resting baseline ECG; able to exercise to target heart rate ($\ge 85%$ of max predicted HR: $220 - \text{age}$). | Positive: $\ge 1\text{ mm}$ horizontal or downsloping ST-segment depression measured 80 ms after J-point. | Inexpensive, widely available. Inconclusive if unable to achieve 85% target HR. Cannot interpret if baseline LBBB, ST abnormalities, or pre-excitation. |
| Stress Echocardiography (Exercise or Dobutamine) | Abnormal baseline ECG, uninterpretable ST segments, or intermediate pre-test probability. | New or worsening regional wall motion abnormalities (RWMA) during stress that resolve at rest (inducible ischemia). | High specificity; assesses valvular pathology and resting LVEF. Operator dependent. |
| Myocardial Perfusion Imaging (SPECT / PET) | Obese patients, prior revascularization, LBBB (requires adenosine/regadenoson pharmacologic stress). | Reversible perfusion defect (tracer uptake reduced on stress, normal at rest = ischemia). Fixed defect (reduced uptake stress + rest = prior infarction/scar). | Excellent sensitivity; quantifies ischemic myocardium. Radiation exposure; attenuation artifacts. |
| Coronary CT Angiography (CCTA) | Low-to-intermediate pre-test probability, atypical chest pain, young to middle-aged adults. | High-resolution anatomic visualization of coronary lumen and plaque (calcified and non-calcified soft plaque). | Extremely high Negative Predictive Value ($>97%$) to rule out CAD. Requires HR control ($<65\text{ bpm}$ with beta-blockers) and IV iodinated contrast. |
| Invasive Coronary Angiography (Catheterization) | High pre-test probability, refractory angina on optimal GDMT, high-risk stress test findings, acute ACS. | Direct visualization of coronary anatomy; hemodynamic pressure wire assessment (Fractional Flow Reserve $\text{FFR} \le 0.80$ indicates flow-limiting stenosis). | Gold Standard. Allows immediate percutaneous coronary intervention (PCI/stenting). Invasive risks (bleeding, dissection, stroke, AKI). |
4. Medical Management of Chronic Coronary Disease (CCD)
The medical management of stable CAD is dual-focused: (1) Prevent major adverse cardiovascular events (mortality/MI reduction), and (2) Relieve anginal symptoms and optimize functional quality of life.
+-----------------------------------------------------------------------------+
| CHRONIC CORONARY DISEASE MEDICAL REGIMEN |
| |
| [DISEASE-MODIFYING / MORTALITY-REDUCING AGENTS] |
| 1. Antiplatelet: Aspirin 81 mg daily (or Clopidogrel 75 mg if allergic) |
| 2. Lipid-Lowering: High-Intensity Statin (Atorvastatin 80 mg / Rosuva 40) |
| 3. Renin-Angiotensin: ACEi or ARB (if HTN, DM, CKD, or LVEF <= 40%) |
| |
| [ANTI-ANGINAL / SYMPTOM-RELIEVING AGENTS] |
| 1. FIRST-LINE: Beta-Blockers (Metoprolol Succinate, Carvedilol, Atenolol) |
| - Target resting HR: 55 to 60 bpm; reduces MVO2 |
| 2. SECOND-LINE / COMBINATION: Dihydropyridine CCB (Amlodipine) |
| - Coronary and peripheral vasodilation |
| 3. LONG-ACTING NITRATES: Isosorbide Mononitrate ER (30-120 mg daily) |
| - Reduces preload; MANDATES 10-14 hr daily nitrate-free interval |
| 4. LATE SODIUM CHANNEL INHIBITOR: Ranolazine (500-1000 mg BID) |
| - No effect on HR or BP; safe in bradycardia/hypotension; prolongs QTc |
| 5. PRN RESCUE: Sublingual Nitroglycerin (0.3-0.4 mg SL q5min x 3 doses) |
+-----------------------------------------------------------------------------+
Critical Clinical Guidance for Anti-Anginal Pharmacotherapy:
- Beta-Blockers (First-Line): First-line therapy for chronic exertional angina. Titrate to a resting heart rate of 55–60 bpm and an exercise HR $<100\text{ bpm}$. Reduces myocardial infarction and mortality in patients with prior MI or LVEF $\le 40%$.
- Long-Acting Nitrates & Nitrate Tolerance: Nitrates undergo vascular biotransformation releasing nitric oxide, stimulating cyclic GMP, and causing potent systemic venodilation (reducing left ventricular end-diastolic volume/preload). Continuous 24-hour nitrate exposure causes nitrate tolerance via sulfhydryl group depletion and vascular superoxide generation. A daily 10 to 14-hour nitrate-free interval (e.g., dosing Isosorbide Mononitrate once daily in the morning, or removing transdermal patches at bedtime) is mandatory to maintain anti-anginal efficacy.
- Sublingual Nitroglycerin (SL NTG) Patient Education:
- Dispense in original amber glass bottle (inactivated by light, heat, and moisture; replace every 6 months after opening).
- At the onset of angina: Instruct patient to sit down (prevents syncope from orthostatic hypotension), place one tablet (0.3–0.4 mg) under tongue, and allow to dissolve.
- The 911 Emergency Rule: If chest discomfort is unimproved or worsening 5 minutes after the first dose, the patient or family must call 911 immediately before taking a second dose. The patient may take up to 3 total doses 5 minutes apart while awaiting EMS.
- Absolute Contraindication: Nitrates + PDE-5 Inhibitors:
[!CAUTION] Fatal Drug-Drug Interaction: Co-administration of any nitrate preparation (SL NTG, isosorbide, transdermal patch) with a Phosphodiesterase-5 (PDE-5) inhibitor (such as Sildenafil or Vardenafil within 24 hours, or Tadalafil within 48 hours) is strictly contraindicated. Combined cyclic GMP accumulation causes catastrophic, refractory systemic vasodilation, profound hypotension, coronary hypoperfusion, fatal arrhythmia, and cardiovascular collapse.
5. Acute Coronary Syndromes (ACS): Clinical Triad & Triage
Acute Coronary Syndrome encompasses three clinical entities resulting from acute coronary atherothrombosis.
+-----------------------------------------------------------------------------+
| ACUTE CORONARY SYNDROME SPECTRUM |
| |
| [ACUTE CHEST PAIN / ACS] |
| | |
| v |
| [EMERGENCY 12-LEAD ECG] |
| | |
| +---------------------------+---------------------------+ |
| | | |
| v v |
| [ST ELEVATION >= 1 mm IN] [NO ST ELEVATION] |
| [>= 2 CONTIGUOUS LEADS OR] - ST depression |
| [NEW LBBB] - T wave inversion|
| | - Normal ECG |
| v | |
| [STEMI] v |
| - Transmural necrosis [HIGH-SENSITIVITY |
| - IMMEDIATE REPERFUSION: CARDIAC TROPONIN]|
| * Primary PCI <= 90 min | |
| * Fibrinolysis <= 30 min +-------------+-----------+|
| | ||
| v vv
| [ELEVATED TROPONIN] [NORMAL TROP]
| = [NSTEMI] = [UNSTABLE ANGINA]
| - Subendocardial necrosis - Ischemia w/o necrosis
+-----------------------------------------------------------------------------+
Clinical Comparison of ACS Classifications:
| ACS Type | 12-Lead ECG Findings | Cardiac Biomarkers (hs-cTn) | Pathophysiology & Emergency Management |
|---|---|---|---|
| Unstable Angina (UA) | Transient ST depression, T-wave inversion, or normal ECG. | Negative / Normal (no myocardial necrosis). | Partial coronary thrombus; ischemia without cell death. Admit for telemetry, DAPT, anticoagulation, invasive risk stratification. |
| NSTEMI | Persistent or transient ST depression, T-wave inversion, or non-specific ST changes. | Positive / Elevated (hs-cTn above 99th percentile URL with rising/falling pattern). | Subendocardial necrosis from non-occlusive or transiently occlusive thrombus. Antiplatelet + anticoagulation; early invasive catheterization within 24–48 hours. |
| STEMI | ST-segment elevation $\ge 1\text{ mm}$ in $\ge 2$ contiguous leads (or $\ge 1.5–2.5\text{ mm}$ in V2–V3 based on sex/age) or new LBBB. | Positive / Elevated (peaks 12–24h). | Complete, acute transmural coronary occlusion. Time is Muscle: Emergent reperfusion via Primary PCI within 90 minutes of FMC (or IV fibrinolysis within 30 minutes if PCI transfer $>120$ minutes). |
6. Post-ACS Outpatient Management: The Five Core Disease-Modifying Pillars
Following hospitalization and discharge for ACS (STEMI or NSTEMI) with or without percutaneous coronary intervention (PCI/stenting), the primary care AGPCNP assumes stewardship of secondary prevention.
+-----------------------------------------------------------------------------+
| THE FIVE CORE DISEASE-MODIFYING POST-ACS PILLARS |
| |
| [PILLAR 1: DUAL ANTIPLATELET THERAPY (DAPT)] |
| - Aspirin 81 mg daily INDEFINITELY |
| - PLUS P2Y12 Inhibitor (Ticagrelor 90 mg BID or Prasugrel 10 mg daily |
| preferred over Clopidogrel 75 mg daily) for AT LEAST 12 MONTHS |
| |
| [PILLAR 2: HIGH-INTENSITY STATIN] |
| - Atorvastatin 80 mg or Rosuvastatin 40 mg daily |
| - Target LDL-C < 70 mg/dL (or < 55 mg/dL); add Ezetimibe if needed |
| |
| [PILLAR 3: BETA-BLOCKER THERAPY] |
| - Metoprolol Succinate, Carvedilol, or Bisoprolol |
| - Continue for AT LEAST 3 YEARS (indefinitely if LVEF <= 40% or CHF) |
| |
| [PILLAR 4: RENIN-ANGIOTENSIN SYSTEM INHIBITION] |
| - ACE Inhibitor (Lisinopril, Ramipril) or ARB (Valsartan, Losartan) |
| - Mandatory for LVEF <= 40%, HTN, Diabetes Mellitus, or CKD |
| |
| [PILLAR 5: MINERALOCORTICOID RECEPTOR ANTAGONIST (MRA)] |
| - Eplerenone (25-50 mg daily) or Spironolactone (25 mg daily) |
| - Indicated post-MI with LVEF <= 40% AND either clinical HF or Diabetes |
| - Criteria: Serum Potassium < 5.0 mEq/L and eGFR >= 30 mL/min |
+-----------------------------------------------------------------------------+
Detailed Pharmacological Pearls for Post-ACS Care:
- P2Y12 Inhibitor Selection & Durations:
- Ticagrelor (90 mg BID): Direct, reversible P2Y12 antagonist. PLATO trial demonstrated superior mortality reduction over clopidogrel. Note: Aspirin dose must not exceed 100 mg daily (high-dose aspirin decreases ticagrelor efficacy). Side effect: Transient dyspnea (20%).
- Prasugrel (10 mg daily): Potent irreversible thienopyridine prodrug (TRITON-TIMI 38). Contraindicated in patients with prior stroke or TIA (excess fatal intracranial hemorrhage). Caution if age $\ge 75$ or weight $<60\text{ kg}$ (reduce dose to 5 mg).
- Clopidogrel (75 mg daily): Irreversible prodrug requiring hepatic CYP2C19 activation. Preferred in patients on triple antithrombotic therapy (OAC + antiplatelet) or with contraindications to newer agents.
- Pain Management Post-ACS (NSAID Avoidance):
[!WARNING] Absolute Ban on NSAIDs in Post-MI Patients: Systemic Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including non-selective agents (ibuprofen, naproxen) and COX-2 inhibitors (celecoxib), are strictly contraindicated in patients with established CAD and prior MI. NSAIDs cause platelet imbalance, renal sodium retention, systemic vasoconstriction, and increase the risk of recurrent myocardial infarction, heart failure exacerbation, and myocardial rupture by up to 40%.
7. Comprehensive Secondary Prevention: Cardiac Rehab & Immunizations
Outpatient secondary prevention extends beyond pharmacotherapy to structured rehabilitation and vaccination:
- Comprehensive Outpatient Cardiac Rehabilitation (Phase II):
- A medically supervised, multi-disciplinary program comprising exercise training, nutritional counseling, smoking cessation, and psychosocial support.
- Class I recommendation for all patients post-ACS, post-PCI, post-CABG, or with stable angina.
- Reduces all-cause mortality by 25–30% and decreases 1-year hospital readmission rates.
- Annual Influenza Vaccination: Influenza infection triggers systemic inflammatory cascades, endothelial dysfunction, and coronary plaque destabilization. Annual influenza vaccination reduces cardiovascular death by ~18% in CAD patients.
- Pneumococcal & COVID-19 Immunizations: High-priority vaccination schedule for all adult and geriatric CAD patients.
A 71-year-old female with a history of hypertension and osteoarthritis presents to the primary care clinic reporting a 3-week history of progressive shortness of breath, generalized fatigue, and mild nausea occurring whenever she climbs stairs or walks more than two blocks. Her symptoms consistently resolve within 5 to 10 minutes of resting on a bench. She denies chest pain, chest pressure, diaphoresis, or palpitations. Her resting 12-lead ECG shows normal sinus rhythm with non-specific ST-T wave changes unchanged from her baseline recording 1 year ago. Which of the following is the most appropriate next step in evaluation?
A 59-year-old male with a history of stable coronary artery disease and exertional angina presents for a regular follow-up appointment. He takes aspirin 81 mg daily, atorvastatin 80 mg daily, and metoprolol succinate 50 mg daily. He carries sublingual nitroglycerin 0.4 mg for acute anginal episodes. During the visit, he asks for a prescription for tadalafil to treat newly developed erectile dysfunction. Which of the following is the most critical clinical instruction the AGPCNP must provide regarding this combination?
A 66-year-old male with type 2 diabetes mellitus is seen in the outpatient clinic for a routine 4-week post-discharge visit following an acute anterior ST-segment elevation myocardial infarction (STEMI). He underwent successful primary PCI with placement of a drug-eluting stent in the left anterior descending artery. Transthoracic echocardiography performed prior to discharge demonstrated an anterior wall motion abnormality with a left ventricular ejection fraction (LVEF) of 35%. He is currently asymptomatic, with BP 122/76 mmHg, HR 62 bpm, and no peripheral edema or pulmonary rales. His current medications are: aspirin 81 mg daily, ticagrelor 90 mg twice daily, atorvastatin 80 mg daily, metoprolol succinate 50 mg daily, and lisinopril 10 mg daily. His serum potassium is 4.3 mEq/L and serum creatinine is 1.0 mg/dL (eGFR 78 mL/min). To optimize guideline-directed post-MI medical therapy and reduce mortality, which of the following medications should be added to his regimen?